Generic Invanz Availability
INVANZ (ertapenem sodium - injectable;intramuscular, iv (infusion))
Manufacturer: MERCK SHARP DOHME
Approval date: November 21, 2001
Strength(s): EQ 1GM BASE/VIAL [RLD]
Has a generic version of Invanz been approved?
No. There is currently no therapeutically equivalent version of Invanz available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invanz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: December 26, 1995
Inventor(s): Betts; Michael J. & Davies; Gareth M. & Swain; Michael L.
Assignee(s): Zeneca Ltd.
The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O).sub.n -- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the --NR.sup.2 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Patent expiration dates:
- November 21, 2015✓✓✓
- May 21, 2016✓
- November 21, 2015
Issued: September 14, 1999
Inventor(s): Zimmerman; Jeffrey A. & Williams; John M. & Bergquist; Paul A. & DiMichele; Lisa M. & DuBost; David C. & Kaufman; Michael J. & Sidler; Daniel R. & Hunke; William A.
Assignee(s): Merck & Co., Inc.
A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.Patent expiration dates:
- May 15, 2017✓
- November 15, 2017✓
- May 15, 2017
- Invanz Consumer Information (Wolters Kluwer)
- Invanz Consumer Information (Cerner Multum)
- Invanz ADD-Vantage Consumer Information (Cerner Multum)
- Invanz Advanced Consumer Information (Micromedex®)
- Invanz AHFS DI Monographs (ASHP)
- Ertapenem Consumer Information (Wolters Kluwer)
- Ertapenem Consumer Information (Cerner Multum)
- Ertapenem Injection Advanced Consumer Information (Micromedex®)
- Ertapenem Sodium AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|